ModifiedUnitedHealthcarePolicy 2025D0003AM

Rituximab (Riabni, Rituxan, Ruxience, Truxima) medical necessity

Defines UnitedHealthcare Commercial Medical Benefit coverage criteria for rituximab products (intravenous, non-oncology indications) including preferred products, general requirements for initial and continuation therapy, and diagnosis-specific medical necessity criteria affecting prescribers and members.

Policy Summary

PayerUnitedHealthcare

PolicyRituximab (Riabni, Rituxan, Ruxience, Truxima) medical necessity

Policy CodePolicy 2025D0003AM

Change TypeMaterial: preferred-product stepIgG4‑RD coverage criteriacoding update

Effective DateSep 1, 2025

Next Review Date

Key ActionPrior authorization is required and prescribers must document diagnosis, specialist involvement where specified, and attest to FDA-label dosing or published evidence for non‑FDA dosing.

SourceLink

POLICY UPDATE CHANGES

Specifies Truxima and Ruxience as preferred rituximab products and requires members already on other rituximab products to change to preferred products unless criteria met.

Added language to indicate rituximab is proven for the treatment of immunoglobulin G4-related disease (IgG4-RD) and specified criteria under which it is medically necessary.

Added ICD-10 diagnosis code D89.84 to applicable codes.

Updated Clinical Evidence and References sections to reflect the most current information.

Archived previous policy version 2025D0003AL.

2preferred rituximab products named

09/01/2025policy effective date

multiple

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

indications listed as medically necessary

12 moauthorization period

severalconditions listed as unproven

Coverage Criteria and Clinical Evidence

Immune thrombocytopenic purpura (ITP) — Initial therapy

Rituximab is proven for the treatment of: Immune thrombocytopenic purpura (ITP). Additional information to support medical necessity review where applicable:

Covered when ALL of the following are met:

For initial therapy

Diagnosis of immune thrombocytopenic purpura (ITP); and
Documented platelet count < 30 x 10^9 / L; and
History of failure, contraindication, or intolerance to one of the following: - Anti-D immunoglobulin - Corticosteroids - Immune globulin - Thrombopoietin receptor agonist (TPO-RA) [e.g., Promacta (eltrombopag), Nplate (romiplostim)] - Splenectomy

Evidence

A randomized open-label phase 3 trial of newly diagnosed adult ITP patients (n=133) evaluated dexamethasone alone versus dexamethasone plus rituximab (375 mg/m^2 weekly x4). Eligible patients had platelet counts ≤25 x10^9/L or ≤50 x10^9/L with bleeding. The primary endpoint, sustained response (platelets ≥50 x10^9/L) at 6 months, was achieved in 58% of the rituximab + dexamethasone group versus 37% with dexamethasone alone (p=0.02). Rituximab was associated with longer time to relapse and time to rescue treatment but a higher incidence of grade 3–4 adverse events in the combination arm; median follow-up was 922 days.
Guideline: The American Society of Hematology (ASH) suggests rituximab as a second-line option for adults with newly diagnosed ITP and platelet count <30 x10^9/L, alongside TPO-RA and splenectomy. Selection among second-line therapies should be individualized based on clinical factors, comorbidities, patient preferences, and access considerations.

Systemic Lupus Erythematosus (SLE) — Evidence summary

Rituximab is medically necessary for the treatment of pemphigus vulgaris when all of the following criteria are met:

For initial therapy

Diagnosis of moderate to severe pemphigus vulgaris; and
Prescribed by or in consultation with a dermatologist or other clinician experienced in autoimmune blistering diseases; and
Initial authorization will be for no more than 12 months

For continuation of therapy

Documentation of clinical response or need for additional cycles to achieve or maintain remission; and

Systemic Lupus Erythematosus (SLE) — Mixed randomized and observational data

Rituximab has mixed randomized and observational evidence in systemic lupus erythematosus (SLE). The randomized trials did not meet primary endpoints, while smaller and open-label studies showed promising signals in refractory disease:

Randomized controlled trials

LUNAR (proliferative lupus nephritis, n=144): addition of rituximab (1000 mg days 1, 15, 168, 182) to mycophenolate mofetil and corticosteroids did not significantly improve renal response at 52 weeks (overall renal response 56.9% vs 45.8%; p=0.18).
EXPLORER (extrarenal moderate-to-severe SLE, n=257): rituximab added to background immunosuppression showed no significant difference versus placebo in major or partial clinical responses at week 52.

Observational and open-label studies

Small open-label and longitudinal studies of refractory SLE (e.g., multi-center studies of 15 and 24 patients) reported improvements in BILAG scores, serologic markers (anti-dsDNA, C3), steroid-sparing effects, and clinical responses in many patients. These studies suggest potential benefit in refractory cases but are limited by size and design.

Billing and Diagnosis Codes

Applicable HCPCS/Codes for rituximab and biosimilarsHCPCS

J3590	Unclassified biologics.
J9311	Injection, rituximab 10 mg and hyaluronidase.
J9312	Injection, rituximab, 10 mg.
J9999	Not otherwise classified, antineoplastic drug.
Q5115	Injection, rituximab-abbs, biosimilar, 10 mg.
Q5119	Injection, rituximab-pvvr, biosimilar (Ruxience), 10 mg.
Q5123	Injection, rituximab-arrx, biosimilar, (Riabni), 10 mg.

Applicable ICD-10 Diagnosis Codes (selected excerpt)ICD-10

D47.Z1	Post-transplant lymphoproliferative disorder (PTLD).
D59.0	Drug-induced autoimmune hemolytic anemia.
D69.3	Immune thrombocytopenic purpura.
D89.84	IgG4-related disease.
G36.0	Neuromyelitis optica.
G35	Multiple sclerosis.
G04.81	Other encephalitis and encephalomyelitis.
L10.0	Pemphigus vulgaris.
L12.0	Bullous pemphigoid.
M05.00	Felty's syndrome, unspecified site.

Applicable ICD-10 Diagnosis Codes (partial list)ICD-10

M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee

1–10 of 70

1/7

Added ICD-10 CodesICD-10

D89.84

IgG4-related disease (ICD-10)

No explicit billing or diagnosis codes in these chunksmixed

No codes listed

ITP platelet eligibility thresholds in cited trial

ITP trial enrollment thresholdsEligible patients had platelet counts ≤ 25 x 10^9/L, or ≤ 50 x 10^9/L if bleeding symptoms were present.

Primary endpoint (sustained response) thresholdPlatelet count ≥ 50 x 10^9/L at 6 months follow-up.

Trial arms dosing contextRituximab arm used 375 mg/m^2 weekly ×4 in combination with dexamethasone; supplemental dexamethasone allowed every 1–4 weeks for up to 6 cycles.

B‑cell repopulation monitoring threshold used in NMO studies

Memory B‑cell repopulation trigger (years 0–2)CD27+ memory B cells > 0.05% in peripheral blood mononuclear cells (used to trigger maintenance dosing during first 2 years).

Prior Authorization, Documentation, and Step Therapy

Step Therapy

Prior Authorization and Preferred-Product Step

Prior authorization is required for rituximab products. Truxima and Ruxience are the preferred rituximab products; coverage will be provided for these products when the Diagnosis-Specific Criteria are met. Coverage for non-preferred products (e.g., Rituxan, Riabni, or other rituximab products) may be granted only when both: (1) there is documentation of intolerance, contraindication, or a serious adverse event to Truxima or Ruxience; and (2) the prescribing physician attests that the same intolerance/contraindication/serious adverse event would not be expected to occur with the requested non-preferred product. For members already on non-preferred rituximab products, continuation of coverage generally requires switching to Truxima or Ruxience unless the non-preferred criteria above are met.

Preferred products: Truxima (rituximab-abbs) and Ruxience (rituximab-pvvr).
Non-preferred: Rituxan (rituximab), Riabni (rituximab-arrx), and other rituximab products.
Prescriber attestation required documenting intolerance/contraindication/serious adverse event to preferred products.

Denial Risk

Background and Definitions

Rituximab intravenous products are monoclonal anti‑CD20 antibody therapies used across multiple non‑oncology autoimmune and immune‑mediated conditions. This policy governs coverage for intravenous rituximab formulations without hyaluronidase (e.g., Riabni, Rituxan, Ruxience, Truxima) for non‑oncology indications and distinguishes those products from the subcutaneous hyaluronidase‑containing formulation (Rituxan Hycela), which is designated unproven and not medically necessary for non‑oncology uses. The policy scope includes indication‑specific medical necessity criteria, preferred‑product step requirements, prior authorization, and duration limits applicable to clinical and billing operations.

Rituximab (intravenous products without hyaluronidase)

Definition'Rituximab' refers to all rituximab products without hyaluronidase (examples: Riabni, Rituxan, Ruxience, Truxima).

Formulation scopeThis definition applies to intravenous rituximab products for non-oncology indications covered by the policy.

Exclusion noteRituxan Hycela (rituximab with hyaluronidase) is treated separately and considered unproven for non-oncology uses in this policy.

Policy Changes and Revision History

2025-09-01policy_revisionLatest

Added coverage criteria establishing rituximab as medically necessary for Immunoglobulin G4-related disease (IgG4-RD) including initial and continuation therapy requirements and restriction against combination with other disease‑modifying therapies; added ICD-10 code D89.84; named Truxima and Ruxience as preferred products and required members on non-preferred products to change to preferred agents unless criteria met; archived prior version 2025D0003AL.

Policy history notes that this version (policy number 2025D0003AM, effective 09/01/2025) archived the previous policy version 2025D0003AL and documents the material changes made to coverage rationale, including additions related to IgG4‑RD and the added ICD‑10 code D89.84. The status is recorded as MODIFIED/CURRENT effective 09/01/2025.

Policy Summary

PayerUnitedHealthcare

PolicyRituximab (Riabni, Rituxan, Ruxience, Truxima) medical necessity

Policy CodePolicy 2025D0003AM

Change TypeMaterial: preferred-product stepIgG4‑RD coverage criteriacoding update

Effective DateSep 1, 2025

Next Review Date

Key ActionPrior authorization is required and prescribers must document diagnosis, specialist involvement where specified, and attest to FDA-label dosing or published evidence for non‑FDA dosing.

SourceLink

On This Page

Reauthorization will be for no more than 12 months

title":"Pemphigus vulgaris — Initial and continuation therapy","type":"criteria_group"},{

Overall, randomized phase III trials failed to meet primary endpoints, while observational data indicate potential utility in selected, refractory patients—supporting a classification of rituximab as unproven/not medically necessary for routine SLE treatment in this policy, but potentially considered in exceptional, refractory situations with supporting documentation.

Memory B‑cell repopulation trigger (after year 2)CD27+ memory B cells > 0.1% thereafter (used to trigger maintenance dosing).

Maintenance monitoring approachSingle maintenance infusion administered when reemerging CD27+ memory B cells exceeded thresholds; individualized re-dosing based on flow cytometry monitoring.

Prescriber Attestations and Denial Risk

Prescriber attestations are required for initial and continuation therapy. Initial requests require the prescriber to attest that dosing is consistent with FDA-approved labeling or, for indications without FDA-approved dosing, that published clinical evidence supports the dosing. Continuation requests require documentation of positive clinical response and the same dosing attestations.

Initial therapy: prescriber attests to FDA-label dosing or published clinical evidence for off-label dosing.
Continuation therapy: documentation of positive clinical response plus prescriber attestation to dosing as above.
Requests may be denied if the prescriber does not provide the required attestations or supporting evidence for off-label dosing.

Prior Authorization

Prior Authorization and Duration Limits

Authorizations (initial and reauthorization) are limited to no more than 12 months for listed indications where specified. Documentation of diagnosis and specialist involvement is required where indicated. Combination therapy rules apply in certain indications (e.g., IgG4-RD exclusion of concurrent disease-modifying therapy).

Initial authorization: when specified by indication, will be for no more than 12 months (operational rule).
Reauthorization: when specified, will be for no more than 12 months.
Documentation: diagnosis confirmation and, where required, specialist prescription/consultation (e.g., neurologist for NMOSD, specialist for IgG4-RD).
Combination therapy restrictions: e.g., IgG4-RD — patient must not receive rituximab concurrently with another disease-modifying therapy such as inebilizumab.

Documentation Required

PTLD — Prior Authorization and Sequencing Considerations

For post-transplant B-lymphoproliferative disorder (PTLD), prior authorization should reflect guideline-based sequencing: rituximab monotherapy is recommended first-line for monomorphic or polymorphic PTLD and may be used as single-agent or as part of multiagent regimens depending on disease and prior reduction of immunosuppression.

Initial authorization for PTLD: diagnosis of PTLD required; initial authorization will be for no more than 12 months.
Rituximab sequencing: monotherapy recommended as first-line for many PTLD presentations; may be part of concurrent chemoimmunotherapy or sequential regimens per guidelines.
Document prior reduction of immunosuppression and specialist involvement where applicable.

Note

Medicare Advantage / LCD Check

Medicare Advantage reviews should verify applicable Local Coverage Determinations (LCDs) and Part B step therapy programs. Coverage and preferred-product criteria for Medicare Advantage members may follow Medicare Part B step therapy rules and LCDs.

Refer to LCD L35026 (Rituximab), L39297, L38920, L37205, and L38268 as applicable.
Preferred therapy criteria for Medicare Advantage members: refer to Medicare Part B Step Therapy Programs and relevant LCDs.
Operational note: Medicare coverage rules (Part B) and LCDs may differ from commercial plan requirements.

Denial Risk

Coverage Change / Denial Triggers and Unproven Indications

Requests may be denied or require a change to preferred products if criteria for non-preferred rituximab use are not met. Denials may also occur for missing documentation, lack of required attestations, or when requests are for unproven (not medically necessary) indications.

Coverage may be denied or require change to Truxima or Ruxience unless documented intolerance/contraindication/serious adverse event to preferred products is provided with physician attestation.
Initial or continuation requests lacking required prescriber attestations or supporting evidence may be denied.
Requests for indications listed as unproven (e.g., systemic lupus erythematosus, idiopathic membranous nephropathy, certain neuropathies) are subject to denial as not medically necessary.

Billing Rule

Diagnosis Code Match Requirement

Ensure that the diagnosis codes billed with rituximab claims match the applicable ICD-10 codes listed in the policy. Claims may be denied if billed with diagnosis codes that are not among the policy's applicable codes.

Verify ICD-10 diagnosis codes align with the indication-specific code list in the policy.
Diagnosis code mismatch is a common trigger for claim denial.

Billing Rule

Adverse Effect / Prior Therapy History Coding

Include adverse effect/history documentation and appropriate diagnosis codes when prior therapy failure or adverse events are used to justify non-preferred product use. Use relevant codes to document adverse effects or history of biologic therapy.

Use codes such as T45.1X5A / T45.1X5D / T45.1X5S for adverse effects of antineoplastic/immunosuppressive drugs.
Use Z92.22 to indicate personal history of monoclonal drug therapy when applicable.

Documentation Required

IgG4-RD — Required Documentation and Denial Triggers

For Immunoglobulin G4-related disease (IgG4-RD), initial and continuation requests require robust documentation per ACR/EULAR classification and specialist involvement. Requests lacking the required classification confirmation, specialist prescription/consultation, or documentation that the patient is not receiving concurrent disease-modifying therapy may be denied.

Initial therapy requirements: diagnosis of IgG4-RD plus confirmation by a positive ACR/EULAR assessment (organ involvement consistent with IgG4-RD; negative exclusion criteria; positive inclusion criteria).
Prescribed by or in consultation with a specialist experienced in IgG4-RD.
Patient must not be receiving rituximab concurrently with another disease-modifying therapy for IgG4-RD (e.g., inebilizumab).
Initial authorization will be for no more than 12 months; reauthorization requires documentation of positive clinical response and specialist involvement.
Denial triggers: missing ACR/EULAR confirmation, lack of specialist involvement, or absence of documentation excluding concurrent disease-modifying therapy.

Documentation Required

HBV Screening and Monitoring Requirement

Safety screening and monitoring for hepatitis B virus (HBV) reactivation is required per FDA boxed warning. Thorough screening for prior HBV infection and ongoing monitoring during therapy is expected and should be documented in the medical record used for prior authorization reviews.

Document HBV screening results and monitoring plan prior to and during rituximab therapy.
Be aware that HBV reactivation can be fatal; FDA recommends thorough screening and monitoring for patients with prior HBV infection.

Note

Use of Clinical Trial Outcomes in Documentation

Include relevant clinical trial outcome definitions and supportive evidence when applicable to justify off-label dosing or continuation beyond typical dosing intervals. Trial endpoints and response definitions (e.g., renal response definitions in lupus nephritis trials, sustained platelet response in ITP trials) may inform documentation of clinical benefit.

Use trial-defined outcomes (e.g., sustained platelet response in ITP, renal response criteria in lupus nephritis) to document clinical benefit for continuation requests.
Provide citations or summaries of the published evidence when attesting to off-label dosing.

Rituxan Hycela (rituximab/hyaluronidase) — policy position

Policy stanceRituxan Hycela (rituximab with hyaluronidase) is considered unproven and not medically necessary for non-oncology indications in this policy.

Alternative guidanceFor oncology indications and Rituxan Hycela use, refer to the Oncology Medication Clinical Coverage policy and NCCN Compendium guidance.

Formulation distinctionRituxan Hycela is the subcutaneous hyaluronidase-containing formulation and is explicitly excluded from the generic 'rituximab' definition used for IV products in this policy.

NMOSD diagnostic workup — required elements

Required serologic testingSerologic testing for anti‑aquaporin‑4 IgG (AQP4‑IgG/NMO‑IgG) must be performed as part of diagnostic confirmation.

Core clinical features (AQP4‑positive)If AQP4‑IgG positive, one core clinical characteristic is required (examples: optic neuritis; acute myelitis; area postrema syndrome; acute brainstem syndrome; symptomatic narcolepsy/diencephalic syndrome; symptomatic cerebral syndrome).

Core clinical features (AQP4‑negative)If AQP4‑IgG negative, two core clinical characteristics are required from the same list (optic neuritis, acute myelitis, area postrema syndrome, acute brainstem syndrome, symptomatic narcolepsy/diencephalic syndrome, symptomatic cerebral syndrome).

IgG4‑RD confirmation — ACR/EULAR classification summary

Confirmation standardDiagnosis of IgG4‑related disease must be confirmed by a positive assessment using the ACR/EULAR classification criteria.

Key ACR/EULAR elementsAssessment requires involvement of ≥1 organ consistent with IgG4‑RD, exclusion criteria negative, and inclusion criteria positive based on clinical, serologic, radiologic, or pathologic findings.

Prescriber and combination therapy requirementsPrescribed by or in consultation with an IgG4‑RD specialist; patient must not be receiving rituximab in combination with another disease‑modifying therapy for IgG4‑RD (e.g., inebilizumab).

ACR/EULAR classification confirmation (IgG4‑RD) — operational definition

Operational confirmation requirementFor coverage, IgG4‑RD must be confirmed by a positive ACR/EULAR assessment demonstrating organ involvement consistent with IgG4‑RD, negative exclusion criteria, and positive inclusion criteria.

Documentation expectationsInitial requests must include specialist involvement or consultation and evidence supporting ACR/EULAR criteria (clinical, serologic, radiology, pathology findings).

Authorization limitsInitial authorization limited to no more than 12 months; reauthorization requires documentation of positive clinical response and is limited to no more than 12 months.

ITP sustained response definition (trial)

Study endpoint definitionSustained response in the ITP trial was defined as platelet count ≥ 50 x 10^9/L at 6 months follow‑up.

Context of endpointPrimary end point used to compare rituximab + dexamethasone versus dexamethasone alone (58% vs 37%, p=0.02).

Median follow‑upMedian time to follow‑up reported as 922 days in the trial.

Complete remission (pemphigus cohort) — study endpoint

Pemphigus complete remission endpointComplete remission defined as achievement of complete response with or without treatment at final follow‑up in the retrospective cohort.

Dosing protocol contextPatients received rituximab 1 g IV on days 1 and 15, with optional 500 mg IV at 6‑month intervals or repeat full dosing if clinically warranted.

Outcome summaryComplete remission rates at final follow‑up were 89% (61% off treatment, 28% on adjuvant treatment); median time to relapse 15 months.

Complete Renal Response (CRR) in LUNAR — trial definition

CRR definition (LUNAR trial)Complete Renal Response (CRR) required normal serum creatinine if abnormal at baseline, or SCr ≤115% of baseline if normal; inactive urinary sediment (<5 RBC/HPF, no RBC casts); and urine protein‑to‑creatinine (UPC) <0.5.

PRR definition (LUNAR trial)Partial Renal Response (PRR) defined as not meeting CRR but having SCr ≤115% of baseline; RBC/HPF ≤50% above baseline and no RBC casts; and specified reductions in UPC depending on baseline UPC.

TimepointPrimary renal response evaluated at Week 52 with monitoring extended through Week 78 for longer follow‑up.

Complete remission (pemphigus study duplicate) — endpoint

Study endpoint (pemphigus duplicate)Complete remission defined as achievement of complete response with or without treatment at final follow‑up (same definition as used in the pemphigus cohort report).

Outcome contextReported complete remission rate was 89% with median time to relapse 15 months; protocol used modified RA fixed‑dose rituximab schedule.

Treatment implicationsPatients not achieving remission after one cycle or who relapsed were reported to benefit from further cycles of rituximab.

BILAG — clinical activity index used in SLE studies

BILAG purposeThe British Isles Lupus Assessment Group (BILAG) index is used to assess disease activity and clinical response in systemic lupus erythematosus studies.

Response categorizationIn cited SLE studies, BILAG scores were used to group responses (e.g., major clinical response, partial clinical response, no clinical response) at specified timepoints.

Use in trial monitoringBILAG assessments were performed serially (e.g., weeks 2–28 or every 1–2 months) to measure clinical changes following B‑cell depletion therapy.